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Background: Mental retardation (MR) affects 2–3% of the human population and some of these cases are
genetically determined. Although several genes responsible for MR have been identified, many cases have
still not been explained.
Methods: We have identified a pericentric inversion of the X chromosome inv(X)(p22.3;q13.2)
segregating in a family where two male carriers have severe MR while female carriers are not affected.
Results: The molecular characterisation of this inversion led us to identify two new genes which are
disrupted by the breakpoints: KIAA2022 in Xq13.2 and P2RY8 in Xp22.3. These genes were not
previously fully characterised in humans. KIAA2022 encodes a protein which lacks significant homology
to any other known protein and is highly expressed in the brain. P2RY8 is a member of the purine
nucleotide G-protein coupled receptor gene family. It is located in the pseudo-autosomal region of the
X chromosome and is not expressed in brain.
Conclusions: Because the haploinsufficiency of P2RY8 in carrier mothers does not have a phenotypic
consequence, we propose that the severe MR of the affected males in this family is due to the absence of
the KIAA2022 gene product. However, screening 20 probands from X linked MR families did not reveal
mutations in KIAA2022. Nonetheless, the high expression of this gene in fetal brain and in the adult
cerebral cortex could be consistent with a role in brain development and/or cognitive function.
T
he genetic basis of non-syndromic mental retardation
(NS MR) is complex and heterogeneous. In the past
5 years, several genes causing non-syndromic X linked
mental retardation (NS XLMR) have been identified using
positional cloning strategies.1 In addition to these findings, a
number of genes involved in syndromic MR conditions have
also been shown to cause NS MR. This is the case for genes
such as RSK2,2 ATR-X,3 MECP2,4 FDG1,5 and ARX.6
However, despite important advances in the field of XLMR,
two major problems still need to be addressed. First, the
number of affected families by far exceeds the number of
identified genes.7 8 This means that a significant number of
disease causing genes remain to be identified. Second, recent
data have shown that a mutation reported as disease causing
in MRX families because it segregates with the disease can be
a simple polymorphism, thereby increasing the number of
families in which the gene defect remains to be identified.9 10
The strategy used to identify MR genes often takes
advantage of linkage studies in large families followed by
sequencing of positional candidate genes. In a number of
other instances, the causative genes were cloned from or near
the breakpoint of a chromosomal rearrangement. Indeed,
X autosome translocation represents one of the most power-
ful means to achieve this goal, especially if a new class of
genes is to be identified.11–13 In female patients, such
rearrangements, when balanced, almost invariably lead to
the inactivation of the normal X chromosome, the translo-
cated X chromosome being active probably because of a
strong selection against a possible inactivation of the
autosomal material.14 Although less frequently reported,
other chromosomal anomalies can be used to identify disease
genes.
We report here on the molecular characterisation of an
X chromosome pericentric inversion inv(X)(q13;p22). The
inversion segregates in a family where two severely mentally
retarded males are carriers of the inversion in two genera-
tions.15 Obligate carriers in this family are clinically normal.
This characteristic led us to hypothesise that the causative
gene (if any) would likely be located in the vicinity of the
Xq13 breakpoint rather than in Xp22.3 which is the pseudo-
autosomal region 1 (PAR1) on the human X chromosome and
in which genes are expressed from both the X and Y chromo-
somes. A gene defect in this region of the human X chromo-
some is known to have visible phenotypic effects in female
patients.15 In addition, recent data show that at least one addi-
tional mental retardation gene lies in the Xq12–q21 region.16
The molecular characterisation of the inv(X)(q13;p22)
chromosomal rearrangement led us to the identification of
two new genes which are interrupted by the breakpoints: the
KIAA2022 gene in Xq13.2 and the P2RY8 gene in Xp22.3. We
have determined the genomic structure of these two genes
and studied their expression. We show that the P2RY8 gene is
located in the pseudoautosomal region, that carrier women
are not affected in this family, and that the P2RY8 transcript
is not expressed in human brain. These data led us to
hypothesise that the phenotype of the mentally retarded
males is caused by the disruption of the KIAA2022 gene in
Xq13 since our data show that the corresponding transcript is
highly expressed in fetal brain and the adult cerebral cortex.
To further assess the role of the KIAA2022 gene in the
aetiology of mental retardation, we screened 20 probands
from Xq13 linked XLMR families for mutations. No muta-
tions or nucleotide variants were identified.
Abbreviations: AR, androgen receptor; BrdU, 5-bromodeoxyuridine;
FISH, fluorescent in situ hybridisation; MR, mental retardation; NS MR,
non-syndromic mental retardation; NS XLMR, non-syndromic X linked
mental retardation; PAR1, pseudoautosomal region 1
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METHODS
Cell culture, RNA isolation, and RT-PCR
All lymphoblastoid cell lines were grown in RPMI 1680
(Gibco BRL, Carlsbad, CA, USA) with 10% fetal bovine serum
in the presence of 0.1 mg/ml of kanamycin at 37 C˚ and 5%
CO2. RNA was prepared using patient’s lymphocytes and the
QuickPrep mRNA purification kit according to the instruc-
tions of the manufacturer (Pharmacia, Newark, NJ, USA).
Human normal tissue RNA was purchased (BD Bioscience,
San Jose, CA, USA). Reverse transcription of 5 mg of total
RNA was performed in 50 ml of 16Superscript reaction buffer
(Gibco BRL) containing 3 ng/ml of dN6, 40 U of RNasin
(Promega, San Luis Obispo, CA, USA), 10 mM dNTP, and
200 U of Superscript II reverse transcriptase (Gibco BRL). RT-
PCR was performed using 1/10th of the first strand reaction.
Northern and southern blot hybridisations
We hybridised human fetal MTN blot II and human brain
MTN blot II (BD Bioscience) with a KIAA2022 cDNA probe
(nucleotides 2966–3735 of the cDNA sequence AY563507)
and a probe for b-actin (BD Bioscience). These probes were
labelled by random priming using [a-32P]dCTP. Hybri-
disation of northern blots were carried out in 50% formamide
buffer at 42 C˚ for 16 h. For Southern blot preparation, DNA
samples were digested with EcoRV, electrophoresed on 1%
agarose gel, and blotted onto Hybond N+ nylon membrane
(Amersham Pharmacia Biotech, Buckinghamshire, UK).
Hybridisation and washing were carried out, respectively, in
56SSC/0.5%SDS/16Denhardt and 0.16SSC/0.1%SDS at 65 C˚
according to standard procedures.
Fluorescent in situ hybridisation
The probes (DNA from BACs) were labelled by random
priming with bio-16-dUTP and in situ hybridised at a final
concentration of 20 ng/ml. The hybridisation signals were
made visible with fluorescein labelled avidin following
standard protocols.19 Chromosomes were counterstained with
propidium iodine diluted in pH 11 antifade.
X chromosome inactivation assay
Primers were designed in the (CAG)n flanking sequences of
the androgen receptor (HUMARA) gene intron 1.20 Forward
primer AR-P1 was 59 labelled (IRD800) and the reverse
primer AR-P2 was unlabelled. Primers sequences were: AR-
P1: IRD800 59 TCCAGAATCTGTTCCAGAGCGTGC 39; AR-P2:
59 GCTGTGAAGGTTGCTGTTCCTCAT 39. A 400 ng sample of
DNA was digested by HpaII and ethanol precipitated. PCR
reactions were performed with 100 ng of DNA both on HpaII
digested and undigested DNA. Affected males in our study
were also tested using the same conditions and were
interpreted for allele size at the AR locus after PCR on
undigested DNA. For these males, PCR reactions on HpaII
digested DNA were also used as digestion quality control (no
amplification product on HpaII digested DNA at the AR locus,
Liacoln, NE, USA). PCR conditions were as follow: 16PCR
buffer, 0.2 mM dNTPs, 1.25 Mg2+, 0.5 U Taq (Gibco BRL) in
20 ml final volume. Annealing temperature was 60 C˚ for 30
total cycles. PCR products were loaded on an automated
sequencer (Li-Cor, Lincoln, NE, USA) and quantification of
the relative intensity of each allele was performed using
OneD Scan software (Scanalytics, Fairfax, VI, USA).
Mutation screening
A total of 23 familial cases of X linked mental retardation
previously linked to the Xq13–q21 region were investigated
(family references and linkage intervals are available from
CES and JG upon request). In each case, DNA from an
affected individual was used for direct sequencing of
KIAA2022. We designed primer pairs for each of the four
coding exons including exon–intron boundary sequences
when applicable. We used the following primers: exon 2
340 bp product, Ex2-1F (59-ACAGGTAAATCCCAGTGAGC-
39) and Ex2-1R (59-ATCCTGGACTCAACCTGTCC-39); exon 3
(part one) 869 bp product, Ex3-1F (59-GTACCAGAAACTGA
TCAAGG-39) and Ex3-1R (59-AGAATAGGTTGACAGACAGC-
39); exon 3 (part two) 636 bp product, Ex3-2F (59-TCAGGAT
TGGGGTTACTTCG-39) and Ex3-2R (59-AGTGTCCCGAGCCA
TATAGC-39); exon 3 (part three) 715 bp product, Ex3-3F (59-
GGGAGTTTCAGTGATGATAG-39) and Ex3-3R (59-AGTGTA
CCTTTTAGGCCT CC-39); exon 3 (part four) 893 bp product,
Ex3-4F (59-CATTTCTGCCACCTGCTCG-39) and Ex3-4R (59-
CTCCAAATTCACTGGATTGG-39); exon 3 (part five) 769 bp
product, Ex3-5F (59-CTCATCCTCTGACTCTGAGC-39) and
Ex3-5R (59-GTGAAAGGGTACTGCAGTCC-39); exon 3 (part
six) 720 bp product, Ex3-6F (59-GACACTAGGAACAC
TAAAGG-39) and Ex3-6R (59-CACATCTGCCATACCAG
AGG-39); exon 3 (part seven) 660 bp product, Ex3-7F
(59-CTTCTGGATGATGACCAACG-39) and Ex3-7R (59-
TGGGACAGTTTCTTTCATGC-39); exon 4 380 bp product,
Ex4-1F (59-CTACATCATACGGCATCTAG-39) and Ex4-2R
(59-ATAGTGCATAAACTACTTGTGC-39). We sequenced all
exons in both forward and reverse directions. Sequencing
was carried out by MWG Biotech, Ebersberg, Germany and
Sequencher software (Gene Codes, Ann Arbor, MI, USA) was
used to analyse sequences and chromatograms.
RESULTS
Clinical histories
The first patient (fig 1, individual III-1) was born as the first
child of unrelated Caucasian parents. His mother had three
healthy girls from a first marriage (fig 1). Pregnancy was
uneventful and delivery was induced at 38 weeks. The child
was born in cephalic presentation with a birth weight of
2720 g and a height of 48.5 cm. In the first weeks, he was
hypotonic and had poor visual pursuit. At 13 months, he had
a first episode of tonic-clonic seizures and was placed on
valproate therapy. EEG indicated a bilateral marked slow
dysrhythmia. Seizures recurred in the context of hyperther-
mia. Gastroeosophageal reflux was noted. At 2 years of age, a
gastric ulcer was diagnosed. He developed spastic quadri-
paresia and underwent surgery for pes calcaneovalgus at the
age 3 years. He was severely hypotonic. A cerebral CT scan
indicated enlarged ventricles. Complete blood count and
serum electrolytes were normal, as were plasma amino acids,
serum isoelectrofocussing of sialotransferrins, and urinary
organic acids. Peripheral lymphocytes karyotype indicated
46,XY,inv(X)(p22.3;q13). His developmental milestones were
delayed: he sat alone at 15 months and walked without
assistance at 3 years. From the age of 2 years on, he started to
exhibit hand stereotypic movements and his poor social
interaction suggested a diagnosis of infantile autism. No
language developed. When evaluated at the age of 12 years,
he was profoundly retarded with permanent stereotypic
movements, grunting, and drooling. On clinical examination,
a mild facial dysmorphia was noted with short philtrum,
short nose with thick tip, tentered upper vermilion border,
and esotropia. Oculogyric crises and spastic quadriparesia
with leg muscle wasting were also noted (figs 2 and 3). A
shawl scrotum was present. Height was at – 2.6 SD, and
weight and head circumference were normal (25th centile).
Complete blood count, serum electrolytes, and liver enzymes
were normal. Plasma amino acids were within the normal
range. Brain MRI indicated moderate brain atrophy, as
exemplified by enlarged ventricles, marked Virchow-Robin
spaces, and a thin corpus callosum. Cerebellar vermis
appeared somewhat small. A thick calvarium was also noted.
Eye fundus and slit lamp examination were normal. He is
attending a special school for the mentally handicapped.
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The second patient is the half-nephew of the first patient
(fig 1, individual IV-6). He was born at term to a 27 year old
G2 P2 Caucasian woman. She was unrelated to the father of
the newborn. She was slightly obese (123 kg at delivery) and
had been so since the end of her second decade. She had a
normal girl aged 7 years from a first marriage. The patient
was born at 38 weeks gestation after caesarean section for
acute fetal distress. His birth weight was 2720 g for a height
of 48.5 cm. Moderate hypotonia and major gastroeosopha-
geal reflux were noted on follow up. He was admitted on
five occasions to the hospital for bronchitis. A cerebral CT
scan indicated frontal cortical atrophy. Karyotype was
46,XY,inv(X)(p22.3;q13). Serum electrolytes, plasma amino
acids, lactic acid, complete blood count, serum isoelectro-
focussing of sialotransferrins, very long chain fatty acids,
and urinary organic acids were within normal range.
Developmental milestones were severely delayed. At 5 years
of age, height was at 22.5 SD, weight at the 25th centile, and
head circumference at 22 SD. No language developed and
stereotypic movements of the hands appeared. He sat at
18 months and walked without aid at 3 years. Only mild
dysmorphic features, similar to those observed in his uncle,
were noted.
In summary, both patients had marked neonatal hypoto-
nia, severely delayed developmental milestones with walking
acquired at 3 years of age, progressive quadriparesia, gastro-
eosophageal reflux, and a diagnosis of infantile autism.
Stereotypic movements of hands were very similar in both
children.
Karyotype and X chromosome inactivation
Chromosome analysis of cultured blood lymphocytes from
the two affected patients III-1 and IV-6 (fig 1) revealed the
presence of a pericentric inversion of the X chromosome
46,XY,inv(X)(p22;q13). Mothers of the patients are both
carriers of this chromosomal rearrangement (data not
shown). X chromosome inactivation was assessed using
both 5-bromodeoxyuridine (BrdU) incorporation analysis in
cultured lymphocytes and determination of the methylation
status at the androgen receptor (AR) locus. The results of
these analyses showed that one of the carrier females (III-7)
has a random X chromosome inactivation pattern (data not
shown). DNA was not available for II-2.
FISH mapping of the breakpoint
In order to localise the breakpoint in Xp22 and Xq13, we
initially performed systematic fluorescent in situ hybridisa-
tion (FISH) using genomic clones originating from these two
chromosomal regions. For this purpose, we used the available
physical maps and sequence information (see Methods) to
establish anchored BAC contigs in the regions of interest
(data not shown). After several rounds of hybridisation
which reduced the critical interval by half at each step (data
not shown), we identified two genomic clones spanning the
inversion breakpoints. These clones are RP11-79C13 localised
in Xq13 and RP11-261P4 localised in the pseudoautosomal
region 1 (PAR1) of the human X chromosome in Xp22.3
(fig 4).
Cloning and sequencing of the breakpoints
Because the Xp22 breakpoint is localised in the pseudoauto-
somal region which is present in two copies in males, we
decided to focus on the Xq13 breakpoint first.
For this purpose we carried out long range PCR reactions
using primers designed to amplify overlapping 10 kb frag-
ments in the critical interval (defined as the interval covered
by the BAC clone RP11-79C13) using the DNA of patient IV-6
as a template. All reactions but one yielded a PCR product of
the expected size (data not shown). The 10 kb fragment
which could not be amplified from the patient’s DNA was
presumed to contain the breakpoint and it was again divided
into approximately 1 kb sub-fragments to perform PCR
amplifications. Again, all but one primer pairs amplified the
Figure 1 Pedigree of the family.
Individuals II-2 and III-7 are carriers of
the inversion. IV-7 is a male fetus who
was terminated because he was a
carrier of the inversion. Affected
individuals are represented with black
symbols. Carrier mothers are shown
with a black dot inside their symbol.
Figure 2 Facial appearance of patient III-1 at age 12. Note esotropia.
Figure 3 General view of patient
III-1 at age 12. Note the dystonic
attitude and muscle wasting of
legs.
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expected size fragment (data not shown). The absence of
amplification of this particular PCR product on the patient’s
DNA localised the Xq13 breakpoint within a putative 1 kb
fragment.
Next, we used a probe localised in this 1 kb fragment to
hybridise a southern blot of the patient’s DNA. An abnormal
EcoRV restriction fragment of 7 kb (that is, the junction
fragment) was detected using this probe instead of the wild
type 8.5 kb restriction fragment detected on a control DNA
(fig 5A). This abnormal restriction fragment was excised
from the gel, cloned, and sequenced. Analysis of the sequence
showed that it originated from Xq13 on one side and Xp22 on
the other side. Direct sequence comparisons allowed us to
map precisely the Xq13 breakpoint at position 8703 in the
sequence of clone RP13-9D14 (GenBank accession number
AL390035) and at position 99184 in the sequence of clone
RP11-261P4 (GenBank accession number AL683870). Using
this information, we designed PCR primers on both sides of
each breakpoint to amplify these regions using the genomic
DNA of the patients as a template. Products of the expected
size were obtained in both cases (fig 5B). Sequencing of these
two PCR fragments revealed that the pericentric inversion
occurred without loss of genetic material except for the
presence of an insertion of 6 bp on the short arm of the
inv(X) (data not shown).
Identification and characterisation of KIAA2022 in
Xq13
The sequences of the Xq13 BACs in the critical region were
analysed using the NIX interface at HGMP (see Methods).
This analysis revealed that the Xq13 breakpoint fell inside a
predicted 180 kb intron inside a gene called KIAA2022. In
order to determine the genomic structure of this gene, we
initially compared the genomic sequence of the BACs in the
vicinity of the breakpoint (clones RP11-130N24 and RP11-
79C13) with the KIAA2022 cDNA (GenBank accession
number XM_291326). To confirm these predictions, we used
RNA isolated from lymphoblastoid cell lines and from
different human tissues to perform RT-PCR experiments
with various primer combinations (data not shown). These
experiments allowed us to determine the exact genomic
structure of the KIAA2022 gene (fig 6). The gene is composed
of four exons spanning 192 kb of genomic DNA. It has an
open reading frame of 4551 bp encoding a putative protein
with 1516 amino acids. It has a very long 39 untranslated
region spanning 5828 bp. The sequence of KIAA2022
previously deposited in GenBank with the accession number
XM_291326 does not contain the correct sequence in the 59
untranslated region. Using 59-RACE experiments we deter-
mined that the first exon of KIAA2022 has a size of 327 bp
(data not shown). The sequence resulting from our analysis is
deposited with GenBank accession number AY563507.
In order to examine the expression of the KIAA2022 gene,
we performed RT-PCR experiments using RNA extracted
from various human tissues (fig 7) and we hybridised adult
and fetal northern blots with a specific probe (fig 8). These
experiments revealed that KIAA2022 is highly expressed in
fetal and adult brain and that it is expression in adult brain is
predominantly in the cerebral cortex and the cerebellum. It is
also expressed in other tissues but to a lesser extent.
Identification and characterisation of P2RY8 in Xp22
Using the same strategy as for Xq13.2, we cloned and
sequenced the Xp22.3 breakpoint. We found that the break-
point lies within the single intron of a gene called P2RY8
(fig 6). This gene has not previously been fully characterised
in humans. It is composed of two exons and has a coding
region of 1077 bp. Its expression was studied using the same
RT-PCR experiments as those performed for KIAA2022.
Using P2RY8 specific primers, we show that the correspond-
ing transcript is highly expressed in lymphocytes (fig 7). A
weaker expression is seen in heart, kidney, and lung.
Expression of KIAA2022 and P2RY8 in the carriers of
the inversion
We used RNA extracted from lymphocytes of the two patients
and one of the carrier females (III-7) to perform RT-PCR
experiments and test the expression of the two genes (fig 7).
This analysis showed that the KIAA2022 transcript is no
longer expressed in the patients’ cells whereas the P2RY8
transcript is detected, although apparently in smaller
amounts than in control samples (fig 7). The amount of
P2RY8 is similar in the cells of the affected patients and the
tested carrier female. This observation is consistent with the
Figure 4 Fluorescent in situ hybridisations of the two BACs spanning
the X chromosome inversion breakpoints. (A) Hybridisation of clone
RP11-79C13 (Xq13.2) on a metaphase of carrier mother III-7. The
normal X chromosome and the chromosome carrying the inversion are
marked with arrows. On the inv(X), two FISH signals are detectable
suggesting that the genomic interval covered by this BAC is interrupted
by the presence of the breakpoint. (B) Hybridisation of clone RP11-
261P4 (Xp22.3) on a metaphase of patient IV-6; the Y chromosome and
the X chromosome carrying the inversion are marked with arrows. Two
signals are visible on the inv(X) and two additional signals are seen on
chromosome 6 (cross hybridisation).
Figure 5 (A) Southern blot of a control DNA (Control +) and the DNA
of patient IV-6 hybridised with a probe corresponding to nucleotides
6559–8265 of the RP11-9D14 clone. An abnormal restriction fragment
is detected on the patient’s DNA (arrow). (B) PCR amplification of the two
breakpoints using the genomic DNA of the patient with the inversion (IV-
6), a control DNA (C +), or no DNA (C 2). Left: Amplification of the
Xp22 breakpoint with flanking primers (986 bp product). Right:
Amplification of the Xq13 breakpoint with flanking primers (963 bp
product). MWM, molecular weight marker. A specific PCR product is
obtained using these primer combinations on the patient’s DNA only.
The two products were sequenced to definitively confirm their origin.
KIAA2022 is disrupted in patients with severe MR 739
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fact that a normal copy of the gene is present on the Y
chromosome in males and that this gene is expressed from
both X chromosomes in females. The carrier mother of
patient IV-6 also expresses KIAA2022, a finding which is in
good agreement with its X chromosome inactivation pattern
(see above).
The direction of transcription of the two genes (telomere to
centromere for KIAA2022 on the long arm and centromere to
telomere for P2RY8 on the short arm) prevents the putative
constitution of a fusion transcript after the occurrence of the
inversion.
Mutation screening in unrelated XLMR families
The fact that the KIAA2022 gene was no longer expressed in
the patients’ cells and the fact that it is highly expressed in
fetal and adult brain made it a good candidate for X linked
mental retardation. Conversely, the fact that P2RY8 is not
expressed in brain and is located in the pseudoautosomal
region made it a poor candidate for this phenotype. We thus
decided to focus our attention on KIAA2022 and to screen a
cohort of 20 unrelated XLMR families linked to the same
interval of the human X chromosome for mutations in the
gene (see Methods). We sequenced the KIAA2022 gene using
genomic DNA of one affected individual from each family.
This analysis failed to reveal any disease causing mutations or
polymorphisms.
DISCUSSION
We cloned the breakpoints of a pericentric inversion which
segregates in a family where two males are affected by severe
mental retardation. Two genes are disrupted by these
breakpoints. One is the KIAA2022 gene in Xq13.2 and the
other is the P2RY8 gene in Xp22.3. The P2RY8 gene is not
expressed in the brain and is located in a region of the human
X chromosome where gene defects often cause a phenotype
in carrier females.15 These data led us to hypothesise that the
phenotype of the affected boys in the present family could be
due to the lack of expression of KIAA2022. Our results
indicate that KIAA2022 is no longer expressed in the cells of
the affected male patients carrying the inversion whereas its
expression is indistinguishable from the wildtype in the cells
of the carrier mothers.
We sequenced the KIAA2022 gene in 20 probands from
Xq13 linked non-syndromic XLMR families without identify-
ing any mutation. This negative result might be explained in
several ways. First, the gene itself may be a rare cause of X
linked mental retardation. Since several new non-syndromic
MR genes are found to be responsible for less than 2% of the
cases which are screened,11 13 testing a larger sample of
families will be necessary before drawing any conclusion. The
second hypothesis is that the phenotype of the patients is not
caused by the absence of expression of KIAA2022 but rather
by the haploinsufficiency of P2RY8. In this case, it would be
very difficult to explain why the carrier mothers in this family
do not have any clinical signs. The fact that they are clinically
normal rather indicates that the haploinsufficiency of P2RY8
is not deleterious. The third hypothesis would be that the
phenotype of the patients is caused by a combination of the
two gene deficits. In this case, it will probably be impossible
to find another case where these two genes are simulta-
neously mutated.
Very little information is available on the function of the
two genes disrupted by the chromosomal breakpoints.
KIAA2022 encodes a large protein of 1516 amino acids. No
known functional motif or significant homology to other
proteins was found after a careful search in available
Figure 6 Drawing of the human X chromosome showing the structure of the two breakpoint regions.
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databases. The genomic structure of this gene is quite
unusual with a first intron of 180 kb and a very large third
exon of more than 4 kb where the vast majority of the coding
region is located. It also has an unusually large 39
untranslated region of 5923 bp. Although KIAA2022 is easily
amplified using human adult or fetal brain RNA in RT-PCR
experiments, no human expressed sequence tag (EST) is
present in the databases for its coding region. In the
corresponding Unigene cluster (Hs.124128), the 25 ESTs all
originate from the 39 UTR. This is also a very unusual finding
for which we currently have no explanation.
More information is available for P2RY8. It was classified
as a member of the purine nucleotide G-protein coupled
receptor family of proteins on the basis of amino acid
sequence homologies.17 It encodes a small protein of 359
amino acids. The biology of the P2Y proteins is complex and
these molecules are known to be involved in a large number
of physiological processes ranging from blood platelet
aggregation to the control of chloride ion fluxes in airway
epithelia.18 We show here that this gene is composed of two
exons separated by a large (70 kb) intron which contains the
breakpoint of the inversion in our family. We also show that
the P2RY8 transcript is not expressed in the brain, and that it
is easily detected in blood lymphocytes in contrast to previous
reports for this tissue.17 The absence of detectable expression
in brain makes it a poor candidate to be responsible for the
neurological phenotype of the patients carrying the peri-
centric inversion.
Since the data obtained for the KIAA2022 gene make it the
more likely candidate to be involved in XLMR, it will now be
necessary to study its expression during the development and
in different regions of the cerebral cortex. In parallel, more
patients with XLMR will need to be screened for mutations in
this gene.
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ELECTRONIC-DATABASE INFORMATION
GenBank accession numbers for clones, genes, and
markers are as follows (http://www.ncbi.nlm.nih.
gov/genbank): AL390035 (RP13-9D14), AL683870
(RP11-261P4), AL139395 (RP11-130N24),
AL359545 (RP13-42E14), AZ520691 (RP11-79C13
SP6 BAC end), AQ282259 (RP11-79C13 T7 BAC
end), XM_291326 (KIAA2022 sequence present in
GenBank before this work), AY563507 (KIAA2022
sequence that we have determined). Genomic clones
were obtained from the Sanger Centre (http://
www.sanger.ac.uk). BAC contigs were built in silico
using the Institute for Genomic Research (TIGR) BAC
end-sequence database at http://www.tigr.org/tdb/
humgen/bac_end_search/bac_end_intro.html and
NIX analysis at the UK Human Genome Mapping
Project (UK HGMP) at http://www.hgmp.mrc.ac.uk/
Registered/Webapp/nix/. Sequence analysis of the
BACs overlapping and near the breakpoints was
performed with database tools and gene prediction
software available in the NIX interface. To search
sequence similarities, the BLAST program was used for
nucleic and protein sequence (http://ncbi.nlm.nih.
gov/blast). To search protein motives, we used
ScanProsite (http://www.expasy.org/tools/scnpsite.
html) and ProfileScan (http://hits.isb-sib.ch/cgi-bin/
PFSCAN).
Figure 7 Expression of KIAA2022, P2RY8, and G3DPH in several
human adult tissues and in fetal brain. G3PDH was used as a control to
check that the same amount of cDNA was present in each sample.
Expression of the same genes was tested in cDNA prepared from the
lymphocyte RNA of patients III-1, IV-6, and the carrier mother III-7. A
control male and female cDNA were also used. In each case, the primers
were selected in two different exons of the tested genes and we checked
that they did not yield amplification products if genomic DNA was used
as a template instead of cDNA. KIAA2022 is highly expressed in brain,
but is no longer expressed in the patients’ lymphocytes. P2RY8 is not
expressed in brain but is highly expressed in control lymphocytes and in
the lymphocytes of the patients and one carrier mother.
Figure 8 Hybridisation of a KIAA2022 probe (nucleotides 2966–3735
of the cDNA sequence AY563507) on northern blots prepared with RNA
isolated from (A) fetal tissues and (B) different regions of the human adult
brain. (C, D) Control hybridisations with an actin probe. The KIAA2022
gene is highly expressed in fetal brain and adult cerebellum and cerebral
cortex.
KIAA2022 is disrupted in patients with severe MR 741
www.jmedgenet.com
 on 11 September 2008 jmg.bmj.comDownloaded from 
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
V Cantagrel, A-M Lossi, D Depetris, M-G Mattei, L Villard, Inserm
U491, Faculte´ de Me´decine de La Timone, 27, Bd. Jean Moulin, 13385
Marseille Cedex 5, France
S Boulanger, L Van Maldergem, Centre de Ge´ne´tique Humaine, Institut
de Pathologie et de Ge´ne´tique, Loverval, Belgium
J Gecz, Department of Genetic Medicine, Women and Children’s
Hospital, Adelaide, Australia
C E Schwartz, Greenwood Genetic Center, One Gregor Mendel Circle,
Greenwood, SC, USA
Financial support to VC from the French Ministry of Research is gratefully
acknowledged. This study was supported in part by a grant from NICHD
(HD26202) to CES.
Conflict of interest: none declared.
*These two authors contributed equally to this work.
REFERENCES
1 Chelly J, Mandel JL. Monogenic causes of X-linked mental retardation. Nat
Rev Genet 2000;2:669–80.
2 Merienne K, Jacquot S, Pannetier S, Zeniou M, Bankier A, Gecz J, Mandel JL,
Mulley J, Sassone-Corsi P, Hanauer A. A missense mutation in RPS6KA3
(RSK2) responsible for non-specific mental retardation. Nat Genet
1999;22:13–4.
3 Guerrini R, Shanahan JL, Carrozzo R, Bonanni P, Higgs DR, Gibbons RJ. A
nonsense mutation of the ATRX gene causing mild mental retardation and
epilepsy. Ann Neurol 2000;47:117–21.
4 Couvert P, Bienvenu T, Aquaviva C, Poirier K, Moraine C, Gendrot C,
Verloes A, Andres C, Le Fevre AC, Souville I, Steffann J, des Portes V,
Ropers HH, Yntema HG, Fryns JP, Briault S, Chelly J, Beldjord C. MECP2 is
highly mutated in X-linked mental retardation. Hum Mol Genet
2001;10:941–6.
5 Lebel RR, May M, Pouls S, Lubs HA, Stevenson RE, Schwartz CE.
Nonsyndromic X-linked mental retardation associated with a missense
mutation (P312L) in the FGD1 gene. Clin Genet 2002;61:139–45.
6 Bienvenu T, Poirier K, Friocourt G, Bahi N, Beaumont D, Fauchereau F, Ben
Jeema L, Zemni R, Vinet MC, Francis F, Couvert P, Gomot M, Moraine C, van
Bokhoven H, Kalscheuer V, Frints S, Gecz J, Ohzaki K, Chaabouni H, Fryns JP,
Desportes V, Beldjord C, Chelly J. ARX, a novel Prd-class-homeobox gene
highly expressed in the telencephalon, is mutated in X-linked mental
retardation. Hum Mol Genet 2002;11:981–91.
7 Ropers HH, Hoeltzenbein M, Kalscheuer V, Yntema H, Hamel B, Fryns JP,
Chelly J, Partington M, Gecz J, Moraine C. Nonsyndromic X-linked mental
retardation: where are the missing mutations? Trends Genet
2003;19:316–20.
8 Stevenson RE, Schwartz CE. Clinical and molecular contributions to the
understanding of X-linked mental retardation. Cytogenet Genome Res
2002;99:265–75.
9 Gomot M, Ronce N, Dessay S, Zemni R, Ayrault AD, Moizard MP, Nivelon A,
Gilgenkrantz S, Dourlens J, des Portes V, Chelly J, Moraine C. TM4SF2 gene
involvement reconsidered in an XLMR family after neuropsychological
assessment. Am J Med Genet 2002;112:400–4.
10 Bourdon V, Philippe C, Martin D, Verloes A, Grandemenge A, Jonveaux P.
MECP2 mutations or polymorphisms in mentally retarded boys: diagnostic
implications. Mol Diagn 2003;7:3–7.
11 Vervoort VS, Beachem MA, Edwards PS, Ladd S, Miller KE, de Mollerat X,
Clarkson K, DuPont B, Schwartz CE, Stevenson RE, Boyd E, Srivastava AK.
AGTR2 mutations in X-linked mental retardation. Science 2002;296:2401–3.
12 Kalscheuer VM, Tao J, Donnelly A, Hollway G, Schwinger E, Kubart S,
Menzel C, Hoeltzenbein M, Tommerup N, Eyre H, Harbord M, Haan E,
Sutherland GR, Ropers HH, Gecz J. Disruption of the serine/threonine kinase
9 gene causes severe X-linked infantile spasms and mental retardation.
Am J Hum Genet 2003;72:1401–1.
13 Kutsche K, Yntema H, Brandt A, Jantke I, Nothwang HG, Orth U,
Boavida MG, David D, Chelly J, Fryns JP, Moraine C, Ropers HH, Hamel BC,
van Bokhoven H, Gal A. Mutations in ARHGEF6, encoding a guanine
nucleotide exchange factor for Rho GTPases, in patients with X-linked mental
retardation. Nat Genet 2000;26:247–50.
14 Waters JJ, Campbell PL, Crocker AJ, Campbell CM. Phenotypic effects of
balanced X-autosome translocations in females: a retrospective survey of 104
cases reported from UK laboratories. Hum Genet 2001;108:318–27.
15 Ross JL, Scott C Jr, Marttila P, Kowal K, Nass A, Papenhausen P, Abboudi J,
Osterman L, Kushner H, Carter P, Ezaki M, Elder F, Wei F, Chen H, Zinn AR.
Phenotypes associated with SHOX deficiency. J Clin Endocrinol Metab
2001;86:5674–80.
16 Sismani C, Syrrou M, Christodoulou K, Hamel B, Chelly J, Yntema HG, van
Bokhoven H, Tzoufi M, Georgiou I, Patsalis PC. A gene for nonsyndromic X-
linked mental retardation (MRX77) maps to Xq12-Xq21.33. Am J Med Genet
2003;122:46–50.
17 Adrian K, Bernhard MK, Breitinger HG, Ogilvie A. Expression of purinergic
receptors (ionotropic P2X1-7 and metabotropic P2Y1-11) during myeloid
differentiation of HL60 cells. Biochim Biophys Acta 2000;1492:127–38.
18 Von Kugelgen I, Wetter A. Molecular pharmacology of P2Y receptors.
Naunyn Schmiedebergs Arch Pharmacol 2000;362:310–23.
19 Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, high
sensitivity fluorescence in situ hybridization. Proc Natl Acad Sci U S A
1986;83:2934–8.
20 Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation
of HpaII and HhaI sites near the polymorphic CAG repeat in the human
androgen-receptor gene correlates with X chromosome inactivation. Am J Hum
Genet 1992;51:1229–39.
742 Cantagrel, Lossi, Boulanger, et al
www.jmedgenet.com
 on 11 September 2008 jmg.bmj.comDownloaded from 
